Respiratory failure & ventilation
Immunological sub-phenotypes and response to convalescent plasma in COVID-19 induced ARDS: a secondary analysis of the CONFIDENT trial
Authors' conclusion
The response to CP was similar across the 4 sub-phenotypes.
Study context
- Population
- Patients with COVID-19 induced ARDS (C-ARDS) in the CONFIDENT trialsampled of 475 in CONFIDENT
- Participants
- 391 patients
- Comparison
- Convalescent plasma vs standard care across immunological sub-phenotypes
- Sub-phenotype-1n = 89
- Sub-phenotype-2n = 178
- Sub-phenotype-3n = 38
- Sub-phenotype-4n = 86
- Primary endpoint
- Association between sub-phenotypes and CP effect on mortality
- Follow-up
- Day 28
Methodological detailsunsupervised hierarchical cluster analysis, biomarker sub-phenotyping, 196/391 (50.1%) assigned to convalescent plasma (CP)
- Unsupervised hierarchical cluster analysis
- Biomarker sub-phenotyping
- 196/391 (50.1%) assigned to CP
Primary result
As reported in the abstract
CP effect on day-28 mortality by sub-phenotype (subgroup)
- Effect of CP on mortality appeared higher than standard care in each sub-phenotype, without heterogeneity between sub-phenotypes
- p = 0.97
Further findings
- Sub-phenotype-2 and sub-phenotype-4 had higher severity at inclusion
Original publication
Immunological sub-phenotypes and response to convalescent plasma in COVID-19 induced ARDS: a secondary analysis of the CONFIDENT trial. Ann Intensive Care. Published 21 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →